For five straight sessions, UnitedHealth Group (NYSE: UNH) had been bleeding — weighed down by litigation headlines, government funding pressure, and a broader skepticism that its Q1 beat was nothing more than a lucky accident of light flu season and weather-related care deferrals. Then Thursday morning changed the narrative entirely. Bank of America upgraded UNH to Buy from Neutral and raised its price target to $450 from $420, implying 19% upside from Wednesday's close. Within the same trading session, Morgan Stanley raised its target to $453 from $395, maintaining its Overweight rating. UNH surged more than 5.7% intraday, snapping the losing streak in emphatic fashion.
The dual-upgrade day coincided with a sector-wide signal. According to Investor's Business Daily, UNH and CVS Health (NYSE: CVS) are now leading all S&P 500 health insurers flashing technical buy signals Thursday — a confluence of analyst conviction and chart momentum that the managed care sector has not seen in months.
